Literature DB >> 12515932

[Fungal keratitis at the Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts: retrospective study of 19 cases].

N Rondeau1, T Bourcier, C Chaumeil, V Borderie, O Touzeau, Y Scat, F Thomas, C Baudouin, J-P Nordmann, L Laroche.   

Abstract

PURPOSE: To report the spectrum of fungal keratitis at the Centre Hospitalier National d'Ophtalmologie XV-XX, Paris.
METHODS: We reviewed 19 cases of fungal keratitis from January 1993 to January 2001. We evaluated the different risk factors, fungal identification, topical and systemic antifungal therapy, surgical treatment and outcome.
RESULTS: Nineteen patients were included, 7 women and 12 men, with visual acuity ranging from 9/10 to no perception of light. The mean age was 56.2 years. Patients were hospitalized for an average stay of 16.3 days and all received a diagnostic and therapeutic scraping and 16 received a local antifungal treatment. The most common risk factors were topical steroid treatment (42.1%), corneal graft (31.6%), trauma or foreign body (31.6%). The mean delay between the first signs and fungal keratitis diagnosis was 14 days. Yeast as Candida parapsilosis and albicans were the most frequently isolated fungi (58%), followed by Aspergillus sp. (21%) and Fusarium sp. (21%). The most commonly used topical treatment was amphotericin B, and itraconazole was used as systemic treatment. Five patients had evisceration, 6 had penetrating keratoplasty and 5 retained leukoma.
CONCLUSION: Candida was the most frequently isolated fungi and topical steroid treatment the main risk factor. The prognosis is relatively poor (26% of lost vision) because of a delay in diagnosis and other previous ocular pathology or surgery.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12515932

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  8 in total

1.  Detection of Aspergillus keratitis in ocular infections by culture and molecular method.

Authors:  Parisa Badiee; Abdolvahab Alborzi; Mahmood Nejabat
Journal:  Int Ophthalmol       Date:  2011-07-13       Impact factor: 2.031

2.  Fungal Keratitis in North India: Spectrum of Agents, Risk Factors and Treatment.

Authors:  Anup K Ghosh; Amit Gupta; Shivaprakash M Rudramurthy; Saikat Paul; Vinay Kumar Hallur; Arunaloke Chakrabarti
Journal:  Mycopathologia       Date:  2016-07-29       Impact factor: 2.574

3.  The efficacy of voriconazole in 24 ocular Fusarium infections.

Authors:  P Troke; G Obenga; T Gaujoux; P Goldschmidt; A-L Bienvenu; M Cornet; F Grenouillet; D Pons; S Ranque; K Sitbon; C Chaumeil; V Borderie; O Lortholary
Journal:  Infection       Date:  2012-06-21       Impact factor: 3.553

4.  A 10-Year Retrospective Clinical Analysis of Fungal Keratitis in a Portuguese Tertiary Centre.

Authors:  Ana Maria Cunha; João Tiago Loja; Luís Torrão; Raúl Moreira; Dolores Pinheiro; Fernando Falcão-Reis; João Pinheiro-Costa
Journal:  Clin Ophthalmol       Date:  2020-11-12

5.  Clinical and Mycological Features of Fungal Keratitis: A Retrospective Single-Center Study (2012-2018)

Authors:  İbrahim İnan Harbiyeli; Elif Erdem; Nuhkan Görkemli; Astan İbayev; Hazal Kandemir; Arbil Açıkalın; Macit İlkit; Meltem Yağmur
Journal:  Turk J Ophthalmol       Date:  2022-04-28

6.  Clinical analysis of microbiologically proven fungal keratitis according to prior topical steroid use: a retrospective study in South Korea.

Authors:  Chan-Ho Cho; Sang-Bumm Lee
Journal:  BMC Ophthalmol       Date:  2019-10-16       Impact factor: 2.209

7.  Keratomycosis after incidental spillage of vegetative material into the eye: Report of two cases.

Authors:  Ali Tabatabaee; Zahra Mohajernezhadfard; Farid Daneshgar; Mohammadreza Mansouri
Journal:  Oman J Ophthalmol       Date:  2013-05

8.  Altered Patterns of Fungal Keratitis at a London Ophthalmic Referral Hospital: An Eight-Year Retrospective Observational Study.

Authors:  Hon Shing Ong; Simon S M Fung; David Macleod; John K G Dart; Stephen J Tuft; Matthew J Burton
Journal:  Am J Ophthalmol       Date:  2016-06-07       Impact factor: 5.258

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.